

AMERICAN VIETNAMESE BIOTECH INC

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024, audited by

NHAN TAM VIET AUDITING COMPANY LIMITED

TABLE OF CONTENTS

Content	Page
Statement of The Board of Management	2-4
Independent Auditors' Report	5-6
Audited financial statements	7-41
<i>The balance sheet as of December 31, 2024</i>	<i>7-10</i>
<i>Income statement for the year 2024</i>	<i>11</i>
<i>Cash flow statement for the year 2024</i>	<i>12-13</i>
<i>Notes to the financial statements for the year 2024</i>	<i>14-41</i>

STATEMENT OF THE BOARD OF MANAGEMENT

The management of American Vietnamese Biotech INC (hereinafter referred to as the "Company") presents its report together with the audited financial statements for the fiscal year ending December 31, 2024.

General information about the Company

American Vietnamese Biotech Incorporation was established under Business Registration Certificate No. 3800237998 issued by the Ho Chi Minh City Department of Planning and Investment on 26 August 2002. During its operation, the Company has amended its business registration certificate 23 times. The 23rd amended Business Registration Certificate for the Joint Stock Company was issued on 05 August 2024.

The charter capital as stipulated in the 23rd Enterprise Registration Certificate: VND 1,311,056,500,000.

Charter capital contributed as at 31 December 2024: VND 1,311,056,500,000.

Head office:

Address : 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan Phu Ward, District 7, Ho Chi Minh City, Vietnam.
Telephone : 0651.3.889034
Fax : 0651.3.889032
Tax code : 3 8 0 0 2 3 7 9 9 8

Financial Situation and Business Operations

The financial situation as of December 31, 2024, along with the business performance and cash flows for the fiscal year ending on the same date, is presented in the Financial Statements attached to this report (from page 07 to page 41).

Significant events occurring during and subsequent to the end of the accounting period

- American Vietnamese Biotech INC ("AMV") with many years of experience in the medical field: providing machinery and equipment systems, supplying consumables,... Facing the increasing demand for health care services, cancer screening and home health care, learning from the infusion center model - built and operated according to Japan's international safety standards - specializing in providing drug, vitamin, protein, therapy and water infusion services to improve patient health, is gradually becoming a popular trend in many countries such as Japan, the US, Thailand. However, in Vietnam, this model is still quite new and has not been widely deployed. At the same time, after reviewing and evaluating the overall mobile examination vehicle project, investment project, joint venture linking medical image archiving and transmission systems (PACS system) with hospitals that the company previously pursued, it did not meet expectations as expected. Therefore, the company boldly divested all or part of those projects, the Company has determined a strategy to strongly develop the clinic and infusion center model in the coming time. Currently, the Company is carrying out the necessary procedures to put the chain of clinic companies in all 63 provinces and cities across the country into operation, with the expectation of providing early, reliable diagnostic tests at the most cost-effective cost at the chain of testing centers. This issue was also approved at the 2024 Annual General Meeting of Shareholders.

- Resolution of the Board of Directors No. 0601/2025/NQ-HĐQT dated January 6, 2025 and Resolution of the Board of Directors No. 1701/2025/NQ-HĐQT dated January 17, 2025 on receiving the transfer of VND 204,227,000,000 of contributed capital at Phu Tho Provincial Obstetrics and Pediatrics Hospital from Sara Vietnam Joint Stock Company. The transfer value from Sara Vietnam Joint Stock Company under contract No. 01/2025/HĐCN/SARA-VIETMY dated February 15, 2025 is VND 204,227,000,000. Up to now, the Company has paid the entire amount of VND 204,227,000,000. However, according to Resolution of the Board of Directors No. 1604/2025/NQ-HĐQT dated April 16, 2025, the Company decided to withdraw capital early from Phu Tho Maternity and Pediatrics Hospital,

AMERICAN VIETNAMESE BIOTECH INCO
STATEMENT OF THE BOARD OF MANAGEMENT (continue)

the capital withdrawal plan is from 2025 to 2028. Up to now, the Hospital has transferred 9,5 billion to the company.

- Resolution of the Board of Directors No. 2502.01/2025/NQ-HDQT dated February 25, 2025 on divestment of investment capital at Vietnam National Software Production Joint Stock Company.

In addition to the above events, the Company's Board of Directors confirms that no other events have occurred up to the date of this report that have not been considered for adjustment of figures or disclosed in the Financial Statements.

THE BOARD OF DIRECTORS AND THE BOARD OF MANAGEMENT

The members of the Board of Directors, the Board of Supervisory Committee and the Board of Management during the year and at the date of this report are:

The Board of Directors

Name	Position
Mr. Nakatani Yoshitaka	Chairman
Ms. Dang Nhi Nuong	Member
Mr. Le Khanh Nguyen	Member

The Board of Supervisory Committee

Name	Position
Ms. Le Thi Huong	Head of Supervisory Committee
Ms. Nguyen Huong Giang	Member
Ms. Vu Thu Thuy	Member

Board of Management

Name	Position
Ms. Dang Nhi Nuong	Director

Chief Accountant

Name
Ms. Le Thi Viet Ha

Auditor

The financial statements for the year ended 31 December 2024 have been audited by Nhan Tam Viet Auditing Company Limited.

The Board of Management's Statement of responsibility

The Board of Management is responsible for preparing the Financial Statements that fairly and accurately reflect the Company's financial position, business performance, and cash flows for the year. During the preparation of the Financial Statements, the Company's Executive Board commits to complying with the following requirements:

- Establishing and maintaining internal controls as determined necessary by the Executive Board and the Board of Directors to ensure that the preparation and presentation of the Financial Statements are free from material misstatements due to fraud or error;
- Selecting appropriate accounting policies and applying them consistently;
- Making reasonable and prudent assessments and estimates;

AMERICAN VIETNAMESE BIOTECH INCO

STATEMENT OF THE BOARD OF MANAGEMENT (continue)

- Stating whether the applied accounting standards have been complied with and disclosing any material deviations that require explanation in the Financial Statements;
- Preparing and presenting the Financial Statements in compliance with the Accounting Standards, the Vietnamese Corporate Accounting System, and relevant legal regulations governing financial reporting;
- Preparing the Financial Statements on a going concern basis unless it is inappropriate to assume that the Company will continue its operations.

The Board of Management ensures that accounting records are maintained to accurately and fairly reflect the Company's financial position at any given time and that the Financial Statements comply with the prevailing regulations of the State. Additionally, the Executive Board is responsible for safeguarding the Company's assets and implementing appropriate measures to prevent and detect fraud and other violations.

The Board of Management commits that the Financial Statements fairly and accurately reflect the Company's financial position as of December 31, 2024, as well as its business performance and cash flows for the fiscal year ending on the same date, in accordance with Accounting Standards, the Vietnamese Corporate Accounting System, and relevant legal regulations governing financial reporting.

Other Commitments

Due to certain objective reasons, the Company has not fulfilled its obligation to publicly disclose the audited financial statements within the prescribed deadline. As a result, the Company's shares have been suspended from trading pursuant to Decision No. 153/QĐ-SGDHN dated 17 March 2025 issued by the Hanoi Stock Exchange. The Company commits to fulfilling this obligation immediately after the issuance of this report together with the audited consolidated financial statements.

Apart from the above issue, the Board of Management confirms that the Company complies with Decree No. 155/2020/ND-CP dated 31 December 2020, providing guidance on corporate governance applicable to public companies, and the Company has not violated the disclosure obligations stipulated in Circular No. 96/2020/TT-BTC dated 16 November 2020 of the Ministry of Finance, guiding information disclosure on the Stock Market.

Ho Chi Minh, 28 May 2025

For and on behalf of the Board of Management,

Director



Dang Nhi Nuong

INDEPENDENT AUDITORS' REPORT

Re: Statements for the year ended 31 December 2024

To : The Shareholders, the Board of Directors and the Board of Management
American Vietnamese Biotech Incorporation

We have audited the accompanying financial statements of American VietNameese Biotech Incorporation, prepared on 28 May 2025 from page 07 to page 41, which comprise the balance sheet as at 31 December 2024, the income statement and cash flow statement for the year then ended and the notes to the financial statements.

The Board of Management's responsibility

The Board of Management of American Vietnamese Biotech Incorporation is responsible for the preparation and fair presentation of these financial statements in accordance with Vietnamese Accounting Standards, Corporate Accounting System and legal regulations relating to preparation and presentation of financial statements, and for such internal control as the Board of Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with Vietnamese Standards on Auditing. These standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified audit opinion.

Basis for Qualified Opinion

- We were unable to observe the cash count as of December 31, 2024, for which the cash on hand was VND 290,950,121, because we had not yet been appointed as the auditor at that time. Accordingly, we do not express an opinion on the existence, accuracy, and completeness of cash as of 31 December 2024.
- Certain associates have been established but have either not yet formed any assets or have formed insignificant assets to support business operations. The total investment in these associates amounts to VND 60,900,000,000 (as disclosed in Note V.12b). Based on the audit procedures performed, we were unable to obtain sufficient appropriate audit evidence to assess the reasonableness of these investments or their impact on the financial statements for the year 2024.
- The Company has invested in and installed machinery, equipment, and the medical image storage and transmission software system (RIS-PACS) according to lease and cooperation agreements with hospitals and medical centers. The total investment as of 31 December 2024, amounted to VND 80,255,898,895 (of

INDEPENDENT AUDITORS' REPORT(CONT)

which VND 59,564,895,987 relates to assets handed over to hospitals for use, and VND 20,691,002,908 relates to assets not yet handed over). Certain hospitals have generated revenue; however, due to the lack of detailed and consistent guidance on payment for diagnostic imaging technical services based on the PACS system, the Company does not yet have sufficient reliable basis to fully determine the economic benefits arising from these leasing and cooperation arrangements. Nevertheless, the Company has recognized depreciation expense for the handed-over assets in the operating results of the years, with accumulated depreciation totaling VND 20,811,796,801 as of 31 December 2024 (of which VND 16,526,054,590 was accumulated as of 31 December 2023, and VND 4,285,742,211 was depreciation expense for year 2024). Based on the audit procedures performed, we were unable to determine the impact of these matters on the financial statements for the year ended 31 December 2024.

Qualified Opinion

In our opinion, except for the matters set forth in the "Basis for Qualified Opinion" paragraph, the accompanying financial statements give a true and fair view of, in all material respects, the financial position of American Vietnamese Biotech Incorporation as at 31 December 2024, and of the results of its operations and its cash flows for the year then ended in accordance with Vietnamese Accounting Standards and Corporate Accounting System and legal regulations relating to preparation and presentation of financial statements.

Emphasis of Matter

As at 31 December 2024, the Company had an overdue loan with Viet Capital Commercial Joint Stock Bank amounting to VND 24,625,095,827. As of the date of this report, the loan remains overdue. The Company had requested a loan extension through Official Letter No. 05/2024/CV-AMV for an extension until October 2024, which was approved by BVBank under Official Letter No. 212/2024/BVbank/CV-QL&THN dated 09 April 2024. However, as of the date of this report, the Company has not fully repaid the outstanding principal and is continuing to work with the bank to request a further extension. (Refer to Note V.17).

Other Matters

The financial statements for the year ended 31 December 2023 of American Vietnamese Biotech Incorporation were audited by another audit firm. Independent Auditor's Report No. 201/BCKT-TC dated 29 March 2024 expressed a qualified opinion due to the auditors' inability to estimate the net realizable value of inventories comprising various types of software, which were presented at historical cost and amounted to VND 140,080,690,416 as at 31 December 2023. As of the date of this report, all of the aforementioned software had been sold and the related receivables had been fully collected. Therefore, this matter no longer affects the financial statements for the year ended 31 December 2024.

In addition, the Independent Auditor's Report for the year 2023 included an Emphasis of Matter paragraph regarding the following matters:

+ The Company has invested in and installed machinery, equipment, and the medical image storage and transmission software system (RIS-PACS) according to cooperation agreements with hospitals and medical centers but has not yet recognized revenue from these activities. This matter has been included in the Basis for Qualified Opinion section of our report.

+ The loan from Viet Capital Commercial Joint Stock Bank as of 31 December 2023 amounted to VND 31,623,165,292 and was overdue. We continue to emphasize this matter in our 2024 audit report.

Hanoi, 28 May 2025

NHAN TAM VIET AUDITING COMPANY LIMITED

Deputy General Director

Auditor



Nguyen Van Tan

Audit Practice Registration Certificate
No. 5348-2025-124-1

Pham Van Tuan

Audit Practice Registration Certificate
No. 4497-2023-124-1

AMERICAN VIETNAMESE BIOTECH INC

4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City, Vietnam.

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

BALANCE SHEET

As of December 31, 2024

Unit: VND

ASSET	Cod e	Explan ation	Year-end Balance	Beginning Balance
A - SHORT-TERM ASSETS	100		181,924,053,900	320,752,651,952
I. Cash and cash equivalents	110	V.1	2,123,348,100	6,404,911,296
1. Cash	111		2,123,348,100	6,404,911,296
2. Cash equivalents	112		-	-
II. Short-term financial investment	120		-	-
1. Trading securities	121		-	-
2. Provision for impairment of trading securities	122		-	-
3. Held to maturity investment	123		-	-
III. Short-term receivables	130		169,243,010,523	153,124,423,200
1. Short-term trade receivables	131	V.2	153,370,344,475	39,531,334,576
2. Short-term vendor advance	132	V.3	9,524,350,514	113,153,578,000
3. Short-term internal receivables	133		-	-
4. Receivable according to construction contract progress plan	134		-	-
5. Short-term loan receivable	135	V.4	500,000,000	-
6. Other short-term receivables	136	V.5	6,107,640,662	514,885,909
7. Provision for doubtful short-term receivables	137	V.6	(259,325,128)	(75,375,285)
8. Assets missing pending resolution	139		-	-
IV. Inventory	140		10,357,695,277	160,972,611,648
1. Inventory	141	V.7	10,357,695,277	160,972,611,648
2. Provision for inventory write-down	149		-	-
V. Other short-term assets	150		200,000,000	250,705,808
1. Short-term prepaid expenses	151	V.8a	-	29,931,820
2. Deductible value added tax	152		-	220,773,988
3. Taxes and other amounts receivable from the State	153	V.14	200,000,000	-
4. Government bond repurchase transaction	154		-	-
5. Other short-term assets	155		-	-

AMERICAN VIETNAMESE BIOTECH INC

4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City, Vietnam.

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Balance Sheet (continued)

ASSET	Cod e	Explan ation	Year-end Balance	Beginning Balance
B - LONG-TERM ASSETS	200		1,485,939,099,062	1,364,943,625,545
I. Long-term receivables	210		-	-
1. Long-term receivables from customers	211		-	-
2. Long-term prepayment to seller	212		-	-
3. Working capital in affiliated units	213		-	-
4. Long-term internal receivables	214		-	-
5. Long-term loan receivable	215		-	-
6. Other long-term receivables	216		-	-
7. Provision for doubtful long-term receivables	219		-	-
II. Fixed assets	220		65,432,066,344	62,694,603,970
1. Tangible fixed assets	221	V.9	26,678,967,158	38,267,230,815
<i>Original price</i>	222		50,034,090,809	64,268,202,914
<i>Accumulated depreciation</i>	223		(23,355,123,651)	(26,000,972,099)
2. Financial lease fixed assets	224		-	-
<i>Original price</i>	225		-	-
<i>Accumulated depreciation</i>	226		-	-
3. Intangible fixed assets	227	V.10	38,753,099,186	24,427,373,155
<i>Original price</i>	228		59,564,895,987	40,953,427,745
<i>Accumulated depreciation</i>	229		(20,811,796,801)	(16,526,054,590)
III. Investment real estate	230		-	-
<i>Original price</i>	231		-	-
<i>Accumulated depreciation</i>	232		-	-
IV. Long-term unfinished assets	240	V.11	20,691,002,908	26,588,372,787
1. Long-term unfinished production and business costs	241		-	-
2. Cost of unfinished basic construction	242		20,691,002,908	26,588,372,787
V. Long-term financial investment	250	V.12	1,399,802,674,180	1,275,629,485,662
1. Investment in subsidiaries	251		1,284,140,000,000	1,289,040,000,000
2. Investment in joint ventures and associates	252		153,300,000,000	-
3. Investing in other entities	253		-	-
4. Long-term financial investment reserve	254		(37,637,325,820)	(13,410,514,338)
5. Held to maturity investment	255		-	-
VI. Other long-term assets	260		13,355,630	31,163,126
1. Long-term prepaid expenses	261	V.8b	13,355,630	31,163,126
2. Deferred income tax assets	262		-	-
3. Long-term replacement equipment, supplies and spare parts	263		-	-
4. Other long-term assets	268		-	-
TOTAL ASSET	270		1,667,863,152,962	1,685,696,277,497

AMERICAN VIETNAMESE BIOTECH INC

4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City, Vietnam.

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Balance Sheet (continued)

CAPITAL SOURCE	Cod e	Explan ation	Year-end Balance	Beginning Balance
C - LIABILITIES PAYABLE	300		122,958,438,171	128,139,839,610
I. Short-term debt	310		122,958,438,171	128,139,839,610
1. Short-term trade payables	311	V.13	1,149,011,676	6,073,280,479
2. Short-term advance payment buyer	312		-	-
3. Taxes and other payments to the State	313	V.14	898,719,173	6,016,462
4. Payable to workers	314		593,880,249	376,678,179
5. Short-term payable expenses	315	V.15	19,760,461,246	13,974,060,840
6. Short-term internal payables	316		-	-
7. Payable according to construction contract progress	317		-	-
8. Short-term unearned revenue	318		-	-
9. Other short-term payables	319	V.16	75,931,270,000	75,931,270,000
10. Short-term loans and finance leases	320	V.17	24,625,095,827	31,778,533,650
11. Provision for short-term payables	321		-	-
12. Bonus and welfare fund	322		-	-
13. Price stabilization fund	323		-	-
14. Government bond repurchase transaction	324		-	-
II. Long-term debt	330		-	-
1. Long-term trade payables	331		-	-
2. Long term prepayment buyer	332		-	-
3. Long-term payable expenses	333		-	-
4. Internal payable on working capital	334		-	-
5. Long-term internal payables	335		-	-
6. Long-term unrealized revenue	336		-	-
7. Other long-term payables	337		-	-
8. Long-term loans and financial leases	338		-	-
9. Convertible bonds	339		-	-
10. Preferred stock	340		-	-
11. Deferred income tax payable	341		-	-
12. Long-term payables provision	342		-	-
13. Science and Technology Development Fund	343		-	-

AMERICAN VIETNAMESE BIOTECH INC

4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City, Vietnam.

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Balance Sheet (continued)

CAPITAL SOURCE	Cod e	Explanat ion	Year-end Balance	Beginning Balance
D - OWNER'S EQUITY	400		1,544,904,714,791	1,557,556,437,887
I. Equity	410	V.18	1,544,904,714,791	1,557,556,437,887
1. Owner's equity	411		1,311,056,500,000	1,311,056,500,000
- Common shares with voting rights	411a		1,311,056,500,000	1,311,056,500,000
- Preferred stock	411b		-	-
2. Capital surplus	412		(395,300,000)	(395,300,000)
3. Bond conversion option	413		-	-
4. Other owners' equity	414		-	-
5. Treasury stock	415		-	-
6. Asset revaluation difference	416		-	-
7. Exchange rate difference	417		-	-
8. Development investment fund	418		-	-
9. Enterprise Reorganization Support Fund	419		-	-
10. Other equity funds	420		-	-
11. Undistributed profit after tax	421		234,243,514,791	246,895,237,887
- Undistributed profit after tax accumulated to the end of the period	421a		246,895,237,887	214,270,463,911
- Undistributed profit this period	421b		(12,651,723,096)	32,624,773,976
12. Source of capital for basic construction investment	422		-	-
II. Other funding sources and funds	430		-	-
1. Funding sources	431		-	-
2. Funds for forming fixed assets	432		-	-
TOTAL CAPITAL	440		1,667,863,152,962	1,685,696,277,497

Prepared by



Nguyen Minh Hoa

Chief Accountant



Le Thi Viet Ha

Prepared on 28 May, 2025

Director



Dang Nhi Nuong

AMERICAN VIETNAMESE BIOTECH INC

4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City, Vietnam.

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

INCOME STATEMENT

For the fiscal year ending December 31, 2024

Unit: VND

INDICATORS	Code	Explanation	This year	Last year
1. Sales and service revenue	01	VI.1	169,364,910,851	53,332,389,363
2. Revenue deductions	02		-	3,028,000
3. Net revenue from sales and services	10		169,364,910,851	53,329,361,363
4. Cost of goods sold	11	VI.2	160,394,730,660	46,892,026,814
5. Gross profit from sales and service provision	20		8,970,180,191	6,437,334,549
6. Financial revenue	21	VI.3	10,000,513,202	43,090,393,468
7. Financial costs	22	VI.4	29,864,843,530	10,951,046,977
Including: interest expense	23		5,638,032,048	7,679,639,455
8. Cost of sales	25	VI.5	321,072,342	1,603,460,952
9. Business management costs	26	VI.6	5,325,865,947	3,891,466,055
10. Net operating profit	30		(16,541,088,426)	33,081,754,033
11. Other income	31	VI.7	3,924,305,576	6,390
12. Other costs	32	VI.8	34,940,246	456,986,447
13. Other profits	40		3,889,365,330	(456,980,057)
14. Total accounting profit before tax	50		(12,651,723,096)	32,624,773,976
15. Current corporate income tax expense	51	VI.9	-	-
16. Deferred corporate income tax expense	52		-	-
17. Profit after corporate income tax	60		(12,651,723,096)	32,624,773,976

Prepared by



Nguyen Minh Hoa

Chief Accountant



Le Thi Viet Ha

Prepared on 28 May, 2025



Dang Nhi Nuong

AMERICAN VIETNAMESE BIOTECH INC

4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City, Vietnam.

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

CASH FLOW STATEMENT

(By indirect method)

For the fiscal year ending December 31, 2024

Unit: VND

INDICATORS	Co de	Explan ation	This year	Last year
I. Cash flow from operating activities				
1. Profit before tax	01		(12,651,723,096)	32,624,773,976
2. Adjustments for the following items:				
- Depreciation of fixed assets and investment real estate	02		9,667,514,548	11,424,411,613
- Provisions	03		24,410,761,325	3,019,169,159
- Exchange rate gains and losses due to revaluation foreign currency monetary items	04		-	-
- Profit and loss from investment activities	05		(13,904,402,106)	(42,904,983,943)
- Interest expense	06		5,638,032,048	7,679,639,455
- Other adjustments	07		-	-
3. Profit from operations before changes in working capital	08		13,160,182,719	11,843,010,260
- Increase, decrease receivables	09		(2,658,596,511)	(34,288,008,619)
- Increase, decrease inventory	10		150,614,916,371	(14,955,108,735)
- Increase, decrease payables	11		(3,462,780,691)	1,454,909,463
- Increase, decrease prepaid expenses	12		47,739,316	168,799,346
- Increase, decrease trading securities	13		-	-
- Interest paid	14		(23,631,642)	(2,001,730)
- Corporate income tax paid	15		(200,000,000)	(1,335,636,262)
- Other income from operating activities	16		-	-
- Other expenses for business activities	17		-	-
Net cash flow from operating activities	20		157,477,829,562	(37,114,036,277)
II. Cash flow from investing activities				
1. Money spent on purchasing and constructing fixed assets and other long-term assets	21		(13,224,968,137)	(125,954,545)
2. Proceeds from liquidation and sale of fixed assets and other long-term assets	22		2,518,500,000	-
3. Money spent on lending, buying debt instruments other units	23		(10,030,000,000)	-
4. Proceeds from loan recovery, resale of debt instruments other units	24		9,530,000,000	-
5. Money spent on investment in other entities	25		(148,400,000,000)	(167,690,000,000)
6. Proceeds from capital investment in other entities	26		-	138,190,000,000
7. Interest income, dividends and profits	27		5,000,513,202	43,018,831,824
Net cash flow from investing activities	30		(154,605,954,935)	13,392,877,279

AMERICAN VIETNAMESE BIOTECH INC

4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City, Vietnam.

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Cash Flow Statement (continued)

INDICATORS	Co de	Explan ation	This year	Last year
III. Cash flow from financing activities				
1. Proceeds from issuing shares, receiving capital contributions owner	31		-	-
2. Money returned to owners, buyback issued company shares	32		-	-
3. Proceeds from borrowing	33		-	-
4. Loan principal repayment	34		(7,153,437,823)	(4,579,635,855)
5. Lease principal repayment	35		-	-
6. Dividends, profits paid to owners	36		-	-
<i>Net cash flow from financing activities</i>	40		<i>(7,153,437,823)</i>	<i>(4,579,635,855)</i>
Net cash flow during the year	50		(4,281,563,196)	(28,300,794,853)
Cash and cash equivalents at the beginning of the year	60	V.1	6,404,911,296	34,705,706,149
Impact of Foreign Exchange Rate Fluctuations on Currency Translation	61		-	-
Cash and cash equivalents at the end of the year	70	V.1	2,123,348,100	6,404,911,296

Prepared by


Nguyen Minh Hoa

Chief Accountant


Le Thi Viet Ha

Prepared on 28 May, 2025

Director



Dang Nhi Nuong

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City
FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements (cont)

NOTES TO THE FINANCIAL STATEMENTS for the fiscal year ending on December 31, 2024

I. OPERATION FEATURES

1. **Ownership form** : Joint Stock Company
2. **Business Sector** : Medical equipment and medical testing chemicals

3. **General information about the Company**

American Vietnamese Biotech Incorporation was established under Business Registration Certificate No. 3800237998 issued by the Ho Chi Minh City Department of Planning and Investment on 26 August 2002. During its operation, the Company has amended its business registration certificate 23 times. The 23rd amended Business Registration Certificate for the Joint Stock Company was issued on 05 August 2024.

The charter capital as stipulated in the 23rd Enterprise Registration Certificate: VND 1,311,056,500,000.

Charter capital contributed as at 31 December 2024: VND 1,311,056,500,000.

Head office:

Address : 4th Floor, Phu Ma Duong Building, No. 85 Hoang Van Thai Street, Tan Phu Ward,
District 7, Ho Chi Minh City, Vietnam.

Telephone : 0651.3.889034

Fax : 0651.3.889032

Tax code : 3 8 0 0 2 3 7 9 9 8

4. **Business sector** :

- Retail of medicines, medical equipment, cosmetics and hygiene products in specialized stores (Details: pharmaceutical business, buying and selling medical equipment, medical testing tools and chemicals);
 - Manufacture of medical, dental, orthopedic and rehabilitation equipment and instruments (Details: Manufacturing medical testing equipment);
 - Production of drugs, pharmaceutical chemicals and medicinal materials (Details: Production and trading of vaccines and medical biological products);
 - Production of cosmetics, soaps, detergents, polishes and cleaning products; Agents, brokers, auctioneers (Details: Agents for consignment of goods, production of plastic products);
 - Real estate business, land use rights owned, used or rented (Details: Real estate business);
 - Water exploitation, treatment and supply; Drainage and wastewater treatment; Scrap recycling; Pollution treatment and other waste management activities;
 - Other professional, scientific and technological activities not elsewhere classified (Details: Technology transfer);
 - Other business lines specifically specified in the Business Registration Certificate./.
- Main business activities: Trading in medical equipment and medical testing chemicals.

5. **Normal production and business cycle**

Normal business production cyclecompany no more than 12 months.

6. **Statement on Comparability of Financial Statements**

The financial statement data for 2024 is entirely consistent and ensures comparability with the financial statement data for 2023.

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City
FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Interim Financial Statements (cont)**6. Employees.**

As of the end of the fiscal year, the company has 30 employees working (the number at the beginning of the year was 17 employees).

7. Business structure:**a, Subsidiary**

Company Name	Head office Totalress	Owners hip ratio	Voting ratio	Main business lines
Viet My Hospital Investment Joint Stock Company	No. 307 Nguyen Du extended street, Nong Trang ward, Viet Tri city, Phu Tho province, Vietnam	83.33%	83.33%	Wholesale of pharmaceuticals and medical instruments, wholesale of medical machinery and equipment
Ha Long Kyoto Technology Development Joint Stock Company	Lot A15, Nam Son Industrial Park, Nam Son Commune, Ba Che District, Quang Ninh Province	99.00%	99.00%	Manufacture of medicines, pharmaceutical chemicals and pharmaceutical materials. Manufacture of ovens, furnaces and kilns
Kyoto Bai Chay Clinic Joint Stock Company	Group 4, Zone 4, Bai Chay Ward, Ha Long City, Quang Ninh, Vietnam	98.00%	98.00%	General and specialized clinics
Song Hau New Technology Application Research Joint Stock Company	Song Hau Industrial Park – Phase 1, Dong Phu Commune, Chau Thanh District, Hau Giang Province, Vietnam	98.00%	98.00%	Manufacture of ovens, furnaces and furnaces
Vietnam National Software Production Joint Stock Company	No. 36 BT5 Phap Van - Tu Hiep Urban Area, Hoang Liet Ward, Hoang Mai District, Hanoi, VN	98.00%	98.00%	Computer programming
Ha Dong Clinic Joint Stock Company	3rd Floor, No. 1 Phuc Thinh, Kien Hung Ward, Ha Dong District, Hanoi City	98.00%	98.00%	General, specialist and dental clinics
Hoa Binh Clinic Joint Stock Company	No. 83 Cu Chinh Lan Street, Dong Tien Ward, Hoa Binh City, Hoa Binh Province, Vietnam	98.00%	98.00%	General, specialist and dental clinics
Viet Tri Clinic Joint Stock Company	No. 307 Nguyen Du extended street, Nong Trang ward, Viet Tri city, Phu Tho province	98.00%	98.00%	General, specialist and dental clinics
Gia Lam High-Tech Clinic Joint Stock Company	18 BT5 Phap Van - Tu Hiep Urban Area, Hoang Liet Ward, Hoang Mai District, Hanoi City, Vietnam	98.00%	98.00%	General, specialist and dental clinics
Medicare Can Tho Clinic Joint Stock Company	No. 408 Nguyen Van Cu Street, An Binh Ward, Ninh Kieu District, Can Tho City, Vietnam	98.00%	98.00%	General, specialist and dental clinics
Medicare Hau Giang Clinic Joint Stock Company	No. 16, 1st Floor, Street No. 14, Area 4, Ward III, Vi Thanh City, Hau Giang Province	98.00%	98.00%	General, specialist and dental clinics
Medicare Soc Trang Clinic Joint Stock Company	1st Floor, No. 438 Le Duan Street, Hamlet 4, Ward 4, Soc Trang City, Soc Trang Province, Vietnam	98.00%	98.00%	General, specialist and dental clinics
Medicare Nga Bay Clinic Joint Stock Company	No. 222, 30/4 Street, Area 5, Lai Hieu Ward, Nga Bay City, Hau Giang Province	98.00%	98.00%	General, specialist and dental clinics
Leopard Solutions Joint Stock Company	No. 34, Road 79, Dinh Hamlet, Tan Phu Trung Commune, Cu Chi District, Ho Chi Minh City, Vietnam	75.00%	75.00%	Computer programming

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Financial Statements (Cont)***b, Indirectly owned subsidiaries:***

Company name	Head office Totalress	Owners hip ratio	Voting ratio	Main business lines
Famicare Thu Duc Joint stock Company	28 Hien Vuong, Hiep Phu Ward, Thu Duc City, Ho Chi Minh City	96.04%	96.04%	General, specialist and dental clinics
Medicare Nha Be Clinic Joint Stock Company	568 Le Van Luong Hamlet 3, Phuoc Kien Commune. Nha Be District, Ho Chi Minh City	96.04%	96.04%	General, specialist and dental clinics
Famicare Vinh Yen Joint Stock Company	2nd Floor, No. 79 Ba Trieu Street, Lien Bao Ward, Vinh Yen City, Vinh Phuc Province, Vietnam	98,00%	98,00%	General, specialist and dental clinics

c, Associate company:

Company name	Head office Totalress	Owners hip ratio	Voting ratio	Main business lines
Golab Phap Van Testing Center Joint Stock Company	Floor 1, Lot BT 5, No. 18 New Urban Area, Phap Van – Tu Hiep, Hoang Liet Ward, Hoang Mai District, Hanoi, Vietnam	35%	35%	General, specialist and dental clinics
Famicare Phap Van Joint Stock Company	Floor 1, Lot BT 5, No. 17 New Urban Area, Phap Van – Tu Hiep, Hoang Liet Ward, Hoang Mai District, Hanoi, Vietnam	35%	35%	General, specialist and dental clinics
Golab Go Vap Testing Center Joint Stock Company	1st Floor, No. 178 Nguyen Thai Son Street, Ward 4, Go Vap District, Ho Chi Minh City.	35%	35%	General, specialist and dental clinics
Nghe An Clinic Joint Stock Company	1st Floor, No. 68 Ho Tong Thoc Street, Block 13, Nghi Phu Ward, Vinh City, Nghe An Province, Vietnam	35%	35%	General, specialist and dental clinics
Ba Dinh Clinic Joint Stock Company	No. 37A Doc Phu San, De La Thanh Street, Ngoc Khanh Ward, Ba Dinh District, Hanoi City, Vietn	49%	49%	General, specialist and dental clinics
Golab Bac Lieu Laboratory Center Joint Stock Company	Ground Floor, No. 210 Ba Trieu Street, Ward 3, Bac Lieu City, Bac Lieu Province, Vietnam	35%	35%	General, specialist and dental clinics
Golab Tien Giang Laboratory Center Joint Stock Company	368A, Phuoc Hoa Hamlet, Phuoc Thanh Commune, My Tho City, Tien Giang Province, Vietnam	35%	35%	General, specialist and dental clinics
Golab Binh Duong Laboratory Center Joint Stock Company	No. 634 Binh Duong Boulevard, Hiep Thanh Ward, Thu Dau Mot City, Binh Duong Province, Vietnam	35%	35%	General, specialist and dental clinics
Famicare Tuyen Quang Joint Stock Company	2nd Floor, No. 23 Hoa Lu Street, Group 01, Phan Thiet Ward, Tuyen Quang City, Tuyen Quang Province, Vietnam	35%	35%	General, specialist and dental clinics
Golab Ha Giang Laboratory Center Joint Stock Company	1st Floor, No. 75 Nguyen Thai Hoc Street, Group 22, Minh Khai Ward, Ha Giang City, Ha Giang Province, Vietnam	49%	49%	General, specialist and dental clinics
Huu Nghi Medicare Clinic Joint Stock Company	No. 179 Giai Phong Street, Dong Tam Ward, Hai Ba Trung District, Hanoi City, Vietnam	49%	49%	General, specialist and dental clinics
Golab Ninh Binh Laboratory Center Joint Stock Company	1st Floor, No. 140 Tue Tinh Street, Nam Thanh Ward, Ninh Binh City, Ninh Binh Province, Vietnam	49%	49%	General, specialist and dental clinics
Golab Vung Tau Laboratory Center Joint Stock Company	No. 745 Vo Van Kiet Street, Long Tam Ward, Ba Ria City, Ba Ria - Vung Tau Province, Vietnam	49%	49%	General, specialist and dental clinics

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City
FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Financial Statements (Cont)

II. FISCAL YEAR, CURRENCY USED IN ACCOUNTING

1. Fiscal year

The Company's fiscal year begins on January 1 and ends on December 31 of each year.

2. Currency used in accounting

The currency used in accounting is Vietnamese Dong (VND) because revenue and expenditure are mainly made in VND.

III. ACCOUNTING STANDARDS AND REGIMES APPLIED

1. Applicable accounting standards

The Company applies accounting standards, Vietnamese Enterprise Accounting Regime issued under Circular No. 200/2014/TT-BTC dated December 22, 2014, Circular No. 53/2016/TT-BTC dated March 21, 2016 amending and supplementing a number of articles of Circular No. 200/2014/TT-BTC and circulars guiding the implementation of accounting standards of the Ministry of Finance in preparing and presenting Financial Statements.

2. Statement on compliance with accounting standards and accounting regimes

The Board of Directors ensures that it has complied with the requirements of accounting standards, the Vietnamese Enterprise Accounting Regime issued under Circular No. 200/2014/TT-BTC dated December 22, 2014, Circular No. 53/2016/TT-BTC dated March 21, 2016 amending and supplementing a number of articles of Circular No. 200/2014/TT-BTC as well as circulars guiding the implementation of accounting standards of the Ministry of Finance in preparing Financial Statements.

IV. ACCOUNTING STANDARDS AND REGIMES APPLIED

1. Basis for preparing financial statements

Financial statements are prepared on the accrual basis of accounting (except for information relating to cash flows).

Users of these interim financial statements should read them together with the interim consolidated financial statements of the Company and its subsidiaries ("the Group") for the six-month period ended 31 December 2024 in order to obtain full information on the financial position, results of operations and cash flows of the Group as a whole.

2. Cash and cash equivalents

Cash includes cash on hand, demand deposits, monetary gold used for value storage purposes, excluding gold classified as inventories used as raw materials for the production of products or goods for sale.

Cash equivalents are short-term investments with a maturity of no more than three months from the date of purchase, which are readily convertible to known amounts of cash and are subject to an insignificant risk of changes in value.

3. Financial investments

Loans

Loans are measured at cost less allowance for doubtful debts. Allowance for doubtful debts on loans is made based on the expected level of loss that may occur.

Investments in subsidiaries, joint ventures and associates

Subsidiary

A subsidiary is an enterprise controlled by the Enterprise. Control is achieved when the Enterprise has the power to govern the financial and operating policies of an investee enterprise so as to obtain benefits from its activities.

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Financial Statements (Cont)

Investments in subsidiaries and associates are initially recorded at cost, including the purchase price or capital contribution plus costs directly related to the investment. In case of investment in non-monetary assets, the cost of the investment is recorded at the fair value of the non-monetary assets at the time of acquisition.

Dividends and profits from periods prior to the investment being purchased are recorded as a reduction in the value of the investment itself. Dividends and profits from periods subsequent to the investment being purchased are recorded as revenue. Dividends received in shares are only tracked by the number of shares increased, not the value of the shares received/recorded at par value.

Provision for losses on investments in subsidiaries and associates is made when the subsidiary or associate suffers a loss, with the provision equal to the difference between the actual capital contributions of the parties in the subsidiary, joint venture or associate and the actual equity multiplied by the ratio of the Enterprise's capital contribution to the total actual capital contributions of the parties in the subsidiary or associate. If the subsidiary or associate is the subject of the Consolidated Financial Statement, the basis for determining the provision for losses is the Consolidated Financial Statement.

Increase or decrease in the provision for investment losses in subsidiaries and associates that must be set up at the end of the fiscal year is recorded in financial expenses.

Investments in equity instruments of other entities

Investments in equity instruments of other entities include investments in equity instruments but the Enterprise does not have control, joint control or significant influence over the investee.

Investments in equity instruments of other entities are initially recorded at cost, including the purchase price or capital contribution plus direct costs related to the investment. Dividends and profits from periods prior to the investment being purchased are recorded as a reduction in the value of the investment itself. Dividends and profits from periods subsequent to the investment being purchased are recorded as revenue. Dividends received in shares are only tracked by the number of Totalitional shares, not recording the value of shares received/recorded at par value (except for state-owned enterprises in accordance with current regulations of law).

Provision for losses on investments in equity instruments of other entities is made as follows:

- For investments in listed shares or for which the fair value of the investment is reliably determined, the provision is based on the market value of the shares.
- For investments whose fair value cannot be determined at the reporting date, provisions are made based on the loss of the investee with the provision equal to the difference between the actual capital contribution of the parties at other entities and the actual equity multiplied by the capital contribution ratio of the Enterprise compared to the total actual capital contribution of the parties at other entities.

Increases and decreases in the provision for investment losses in equity instruments of other entities that need to be set up at the end of the fiscal year are recorded in financial expenses.

4. Accounts Receivable

Accounts receivable are stated at carrying amount less allowance for doubtful debts.

The classification of receivables as trade receivables and other receivables is carried out according to the following principles:

- Trade receivables reflect commercial receivables arising from purchase-sale transactions between the company and buyers who are independent entities, including receivables from export sales entrusted to other entities.
- Other receivables reflect non-commercial receivables not related to purchase and sale transactions.

Provision for doubtful debts is made for each doubtful debt based on the age of overdue debts or the expected level of loss that may occur, specifically as follows:

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Financial Statements (Cont)

- For overdue receivables:
 - 30% of the value for overdue receivables from 6 months to less than 1 year.
 - 50% of the value for overdue receivables from 1 year to less than 2 years.
 - 70% of the value for receivables overdue from 2 years to less than 3 years.
 - 100% of the value for receivables 3 years or more old.
- For receivables that are not overdue but are unlikely to be recovered: establish provisions based on expected loss level.

5. Inventory

Inventories are goods and are stated at the lower of cost and net realizable value. The cost of inventories is determined including the cost of purchase and other directly relevant costs incurred in bringing the inventories to their present location and condition.

Net realizable value is the estimated selling price of inventories in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale. Inventories are valued at cost using the weighted average method and accounted for using the perpetual inventory method.

Provision for inventory devaluation is established for each inventory item whose original cost is greater than its net realizable value. For unfinished services, provision for devaluation is calculated for each type of service with a separate price. Increases and decreases in the balance of provision for devaluation of inventory required to be established at the end of the fiscal year are recorded in cost of goods sold.

6. Prepaid expenses

Prepaid expenses include actual expenses that have been incurred but are related to the results of production and business activities of many accounting periods. The company's prepaid expenses are the cost of tools and equipment.

Tools, instruments

Tools and equipment put into use are allocated to expenses using the straight-line method with an allocation period of no more than 03 years.

7. Tangible fixed assets

Tangible fixed assets are stated at cost less accumulated depreciation. The cost of tangible fixed assets includes all costs incurred by the company to acquire the fixed assets up to the time the assets are ready for use. Expenses incurred after initial recognition are only recorded as an increase in the cost of fixed assets if it is certain that these costs will increase future economic benefits from the use of the assets. Expenses incurred that do not satisfy the above conditions are recorded as production and business expenses in the period.

When tangible fixed assets are sold or disposed of, their cost and accumulated depreciation are eliminated from the accounts and any gain or loss resulting from their disposal is recognized as income or expense in the year.

Tangible fixed assets are depreciated using the straight-line method over their estimated useful lives. The depreciation years for various types of Tangible Fixed Assets are as follows:

<u>Type of fixed asset</u>	<u>No. 5</u>
Machinery and equipment	06-10

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Financial Statements (Cont)

8. Intangible fixed assets

Intangible fixed assets are stated at cost less accumulated depreciation.

The original cost of intangible fixed assets includes all costs that Company must be spent to acquire fixed assets up to the time the asset is ready for use. Expenditures relating to intangible fixed assets incurred after initial recognition are recognised as expenses in the period in which they are incurred, unless they are associated with a specific intangible fixed asset and result in an increase in the economic benefits derived from the asset.

Intangible fixed assets of Company include:

Software program

Costs relating to computer software programs that are not part of the related hardware are capitalized. The cost of computer software is the total cost incurred by the Company up to the date the software is put into use. Computer software is amortized on a straight-line basis over 10-20 years.

9. Cost of unfinished basic construction

Construction in progress reflects directly related costs (including including interest expenses related to the Company's accounting policies) to assets under construction, machinery and equipment being installed for production, leasing and management purposes as well as costs related to repairs of fixed assets in progress. These assets are recorded at original cost and not depreciated.

10. Accounts Payable and Accrued Expenses

Liabilities and accruals are recognized for amounts to be paid in the future for goods and services received. Accruals are recognized based on reasonable estimates of the amounts to be paid.

The classification of payables as trade payables, accrued expenses, internal payables and other payables is carried out according to the following principles:

- Trade payables reflect commercial payables arising from transactions of purchasing goods, services, assets and the seller is an independent entity of the company, including payables when importing through consignees.
- Payable expenses reflect amounts payable for goods and services received from sellers or provided to buyers but not yet paid due to lack of invoices or insufficient accounting records and documents, and amounts payable to employees for leave wages, production and business expenses that must be accrued in advance.
- Other payables reflect non-commercial payables not related to the purchase, sale or provision of goods and services.

11. Equity

Owner's equity

Owner's equity is recorded according to the actual capital contributed by shareholders.

Capital surplus

Share capital surplus is recorded as the difference between the issue price and the par value of shares when first issued, Totalitional issued or the difference between the reissue price and the book value of treasury shares. Direct costs related to the Totalitional issuance of shares and reissuance of treasury shares are recorded as a decrease in share capital surplus.

Other owners' equity

Other capital is formed by supplementing from business results, revaluation of assets and the remaining value between the fair value of donated, presented, and sponsored assets after deducting taxes payable (if any) related to these assets.

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Financial Statements (Cont)

12. Profit distribution

Profit after corporate income tax is distributed to shareholders after setting aside funds according to the Company's Charter as well as legal regulations and approved by the General Meeting of Shareholders.

The distribution of profits to shareholders takes into account non-cash items in undistributed earnings that may affect cash flows and the ability to pay dividends. Gains from revaluation of assets contributed as capital, gains from revaluation of monetary items, financial instruments and other non-monetary items.

Other funds

Funds are set aside and used in accordance with the Company Charter and the Resolution of the Annual Shareholders' Meeting.

Dividends are recognized as liabilities when approved by the General Meeting of Shareholders.

13. Revenue and income recognition

a) Sales revenue

Revenue from the sale of goods is recognized when all of the following conditions are simultaneously satisfied:

- The company has transferred to the buyer the significant risks and rewards of ownership of the products or goods.
- The Company no longer holds title to the goods or control over the goods.
- Revenue is determined with relative certainty. When the contract stipulates that the buyer has the right to return the purchased products or goods under specific conditions, revenue is only recognized when those specific conditions no longer exist and the buyer is not entitled to return the products or goods (except in cases where the customer has the right to return the goods in exchange for other goods or services).
- The Company has obtained or will obtain economic benefits associated with the sale transaction.
- Identify the costs associated with a sales transaction

b) Service revenue

Revenue from a service transaction is recognised when the outcome of the transaction can be measured reliably. In cases where the service is performed over several periods, revenue is recognised in each period based on the results of the work completed at the end of the accounting period. The outcome of a service transaction is recognised when all of the following conditions are met:

- Revenue is measured reliably. When a contract provides that the buyer has the right to return the services purchased under specific conditions, revenue is recognized only when the specific conditions no longer exist and the buyer has no right to return the services provided.
- It is possible to obtain economic benefits from the transaction of providing that service.
- Determine the portion of work completed as of the end of the fiscal year.
- Identify the costs incurred for the transaction and the costs to complete the transaction to provide that service.

c) Interest

Interest is recognized on an accrual basis, determined on the deposit account balance and the actual interest rate for each period.

d) Dividends and profits distributed

Dividends and profits distributed are recognized when the company is entitled to receive dividends or profits from capital contributions. Dividends received in shares are only tracked by the number of shares increased, not recorded at par value of shares received.

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Financial Statements (Cont)

14. Cost of goods sold.

Cost of goods sold during the year is recorded in accordance with revenue generated during the period and ensures compliance with the principle of prudence.

15. Borrowing costs

Borrowing costs include interest and other costs incurred in connection with borrowing.

16. Corporate income tax

Current income tax

Current income tax is the tax that is calculated on taxable income. Taxable income differs from accounting profit due to adjustments for temporary differences between tax and accounting, non-deductible expenses as well as adjustments for non-taxable income and losses carried forward.

17. Financial instruments

i. Financial assets

Classification of financial assets

The Company classifies its financial assets into the following groups: financial assets at fair value through the Statement of Business Performance, investments held to maturity, loans and receivables, and available-for-sale financial assets. The classification of these financial assets depends on the nature and purpose of the financial assets and is determined at the time of initial recognition.

Financial assets are recorded at fair value through the Statement of Business Performance

Financial assets are classified as measured at fair value through the Statement of Income if they are held for trading or designated as such at fair value through the Statement of Income upon initial recognition.

Financial assets are classified as held for trading securities if:

- Purchased or created primarily for the purpose of resale in the short term;
- The Company intends to hold for the purpose of short-term profit;
- Derivative financial instruments (except for derivative financial instruments that are identified as a financial guarantee contract or a designated and effective hedging instrument).

Held to maturity investments

Held-to-maturity investments are non-derivative financial assets with fixed or determinable payments and fixed maturity that the Company has the intention and ability to hold to maturity.

Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments and are not listed on an active market.

Financial assets available for sale

Available-for-sale financial assets are non-derivative financial assets that are designated as available-for-sale or that are not classified as financial assets at fair value through profit or loss, held-to-maturity investments, or loans and receivables.

Initial book value of financial assets

Financial assets are recognised at the date of acquisition and derecognised at the date of sale. At the time of initial recognition, financial assets are measured at their purchase price/issuance costs plus any other costs directly attributable to the acquisition or issue of the financial asset.

ii. Financial liabilities

The Company classifies financial liabilities into groups: financial liabilities recorded at fair value through the Income Statement, financial liabilities determined at amortized cost. The classification of financial liabilities depends on the nature and purpose of the financial liability and is determined at the time of initial recognition.

Financial liabilities are recorded at fair value through the Statement of Income.

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Financial Statements (Cont)

A financial liability is classified as measured at fair value through the Statement of Income if it is held for trading or designated as such at fair value through the Statement of Income upon initial recognition.

Financial liabilities are classified as held for trading securities if:

- Issued or created primarily for the purpose of repurchasing in the short term;
- The Company intends to hold for the purpose of short-term profit;
- Derivative financial instruments (except for derivative financial instruments that are identified as a financial guarantee contract or a designated and effective hedging instrument).

Financial liabilities are measured at amortized cost.

Financial liabilities are measured at amortised cost, which is the amount at which the financial liability is initially recognised minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and minus any reduction (directly or through the use of an allowance account) for impairment or uncollectibility.

The effective interest method is a method of calculating the amortized cost of a financial liability or group of financial liabilities and allocating interest income or expense over the relevant period. The effective interest rate is the rate at which estimated future cash flows that will be paid or received over the expected life of the financial instrument or, if appropriate, shorter, are discounted to the net present carrying amount of the financial liability.

Initial book value of financial liability

At initial recognition, financial liabilities are measured at issue price plus any costs directly attributable to the issue of the financial liability.

iii. Equity instruments

An equity instrument is a contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.

18. Related parties

Parties are considered to be related if one party has the ability to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control or common significant influence.

In considering any related party relationship, attention is directed more to the substance of the relationship than to the legal form.

In considering any related party relationship, attention is directed more to the substance of the relationship than to the legal form.

Transactions with related parties during the period are presented in note VII.1.

V. SUPPLEMENTARY INFORMATION FOR ITEMS PRESENTED IN THE BALANCE SHEET

1. Cash and cash equivalents

	Year-end Balance	Beginning Balance
Cash	290,950,121	4,763,319,595
Non-term bank deposits	1,832,397,979	1,641,591,701
Total	2,123,348,100	6,404,911,296

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Financial Statements (Cont)**2. Short-term receivables from customers**

	Year-end Balance		Beginning Balance	
	Value	Provision	Value	Provision
<i>Receivables from related parties (*)</i>	82,715,368,400	-	-	-
Huu Nghi Medicare Clinic Joint Stock Company	244,200,000	-	-	-
Golab Phap Van Test Center Joint Stock Company	242,000,000	-	-	-
Golab Hai Phong Test Center Joint Stock Company	2,932,070,200	-	-	-
Golab Hai Duong Test Center Joint Stock Company	7,159,494,700	-	-	-
Golab Hung Yen Test Center Joint Stock Company	7,013,194,700	-	-	-
Golab Quang Binh Test Center Joint Stock Company	2,913,210,200	-	-	-
Golab Dong Thap Test Center Joint Stock Company	2,768,270,200	-	-	-
Golab Vinh Long Test Center Joint Stock Company	2,768,270,200	-	-	-
Golab An Giang Test Center Joint Stock Company	2,725,370,200	-	-	-
Famicare Kien Giang Joint Stock Company	4,335,384,500	-	-	-
Golab Kien Giang Test Center Joint Stock Company	6,767,870,200	-	-	-
Golab Bac Ninh Test Center Joint Stock Company	7,128,594,700	-	-	-
Golab Vinh Phuc Test Center Joint Stock Company	7,364,884,500	-	-	-
Golab Ninh Binh Laboratory Center Joint Stock Company	42,900,000	-	-	-
Golab Ha Tinh Test Center Joint Stock Company	4,385,784,500	-	-	-
Famicare Quang Binh Joint Stock Company	4,315,384,500	-	-	-
Golab Bien Hoa Test Center Joint Stock Company	4,042,500,000	-	-	-
Golab Gia Lai Test Center Joint Stock Company	2,832,870,200	-	-	-
Famicare Vinh Long Joint Stock Company	7,075,694,700	-	-	-
Golab Tan An Test Center Joint Stock Company	2,822,420,200	-	-	-
Viet My Hospital Investment Joint Stock Company	2,835,000,000	-	-	-
<i>Receivables from other customers</i>	70,654,976,075	(259,325,128)	39,531,334,576	(75,375,285)
Ha Cuong Investment and Trading Limited Liability Company	-	-	6,747,955,200	-
Nhat Medical Equipment Limited Liability Company	-	-	8,642,123,175	-
G7 High Technology Joint Stock Company	-	-	18,370,000,000	-
Lou Investment Joint Stock Company (*)	18,302,003,421	-	-	-
Can Tho Laboratory and Environmental Center Joint Stock Company (*)	45,502,587,900	-	-	-
Other customers	6,850,384,754	(259,325,128)	5,771,256,201	(75,375,285)
Total	153,370,344,475	(259,325,128)	39,531,334,576	(75,375,285)

(*) These receivables had been fully settled as of the date of issuance of this report.

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City
FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Financial Statements (Cont)

3. Short-term seller advance

	Year-end Balance		Beginning Balance	
	Value	Provision	Value	Provision
<i>Advance payment to related parties</i>	-	-	46,000,000,000	-
Viet Tri Clinic Joint Stock Company	-	-	46,000,000,000	-
<i>Prepay to other sellers</i>	9,524,350,514	-	67,153,578,000	-
Can Tho Environment and Test Center Joint stock Company	-	-	20,000,000,000	-
Japan Kanpeki Joint stock Company	3,769,563,726	-	-	-
High-Tech Medical Environment Company Limited	-	-	2,099,000,000	-
Nha Trang Medical Hi-Tech Application Joint Stock Company (*)	5,000,000,000	-	45,000,000,000	-
Other suppliers	754,786,788	-	54,578,000	-
Total	9,524,350,514	-	113,153,578,000	-

(*) These are advances for the purpose of purchasing machinery, software, and medical equipment for production and business activities. However, due to the deadline for providing the machines, the parties have terminated the contract and returned the money. As of the date of issuance of this report, the Company has recovered the entire amount of the advance.

4. Short-term loans receivable

This is a capital support provided to Golab Binh Duong Laboratory Center Joint Stock Company, which has been fully recovered as of the date of issuance of this report.

5. Other short-term receivables

	Year-end Balance		Beginning Balance	
	Value	Provision	Value	Provision
<i>Receivables from related parties</i>	5,000,000,000	-	-	-
Vietnam National Software Production JSC – Dividends and distributed profits receivable	5,000,000,000	-	-	-
<i>Receivables from other organizations and individuals</i>	1,107,640,662	-	514,885,909	-
Social insurance	-	-	1,212,112	-
Advance payment	169,775,746	-	181,620,350	-
Deposits and collaterals	937,864,916	-	332,053,447	-
Total	6,107,640,662	-	514,885,909	-

6. Bad debt

	Year-end Balance		Beginning Balance	
	Original price	Recoverable value	Original price	Recoverable value
Hau Giang Tuberculosis and Lung Hospital	35,168,802	-	35,168,802	-
Phu Tho Provincial General Hospital	25,420,002	-	25,420,002	12,710,001
Gia Rai Town Medical Center	27,496,482	-	27,496,482	-
Central Lung Hospital	171,239,842	-	-	-
Total	259,325,128	-	88,085,286	12,710,001

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Financial Statements (Cont)**7. Inventory**

	Year-end Balance		Beginning Balance	
	Value	Provision	Value	Provision
Goods (*)	10,357,695,277	-	160,972,611,648	-
Total	10,357,695,277	-	160,972,611,648	-

(*) As of January 1, 2024, the inventory included software valued at VND 140,080,690,416, which has subsequently been sold and the related receivables fully recovered.

8. Prepaid expenses**a. Short-term prepaid expenses**

	Year-end Balance	Beginning Balance
Other short-term prepaid expenses	-	29,931,820
Total	-	29,931,820

b. Long-term prepaid expenses

	Year-end Balance	Beginning Balance
Other long-term prepaid expenses	13,355,630	31,163,126
Total	13,355,630	31,163,126

9. Tangible fixed assets

	Machinery and equipment	Total
Original Cost		
Beginning Balance	64,268,202,914	64,268,202,914
Completed capital construction investment	840,453,107	840,453,107
Disposal of assets	(15,074,565,212)	(15,074,565,212)
Year-end Balance	50,034,090,809	50,034,090,809
<i>Including:</i>		
Fully depreciated but still in use	7,392,200,000	7,392,200,000
Accumulated depreciation		
Beginning Balance	26,000,972,099	26,000,972,099
Depreciation during the year	5,381,772,337	5,381,772,337
Disposal of assets	(8,027,620,785)	(8,027,620,785)
Year-end Balance	23,355,123,651	23,355,123,651
Remaining Value		
Beginning Balance	38,267,230,815	38,267,230,815
Year-end Balance	26,678,967,158	26,678,967,158

Some tangible fixed assets are machinery and equipment with original cost and residual value of VND 38,916,611,293 and 24,961,030,796 VND is being mortgaged for the loan at Viet Capital Commercial Joint Stock Bank.

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Financial Statements (Cont)**10. Intangible fixed assets**

	<u>Software program</u>	<u>Total</u>
Original price		
Beginning Balance	40,953,427,745	40,953,427,745
Completed capital construction investment	18,611,468,242	18,611,468,242
Year-end Balance	<u>59,564,895,987</u>	<u>59,564,895,987</u>
<i>In there:</i>		
Fully depreciated but still in use	-	-
Depreciation value		
Beginning Balance	16,526,054,590	16,526,054,590
Depreciation during the year	4,285,742,211	4,285,742,211
Year-end Balance	<u>20,811,796,801</u>	<u>20,811,796,801</u>
Residual value		
Beginning Balance	24,427,373,155	24,427,373,155
Year-end Balance	<u>38,753,099,186</u>	<u>38,753,099,186</u>

The company's intangible fixed assets are the Pacs Software System:

This is a RIS – PACS medical image storage and transmission system that has been installed synchronously by the Company to serve medical examination and treatment, image diagnosis, and accompanying hardware installed at medical facilities (General Hospitals, Medical Centers of provinces/cities) according to the Agreement on cooperation in installation, trial use or business cooperation between the Company and medical facilities and has been accepted by the medical facilities and put into operation.

In some hospitals, there has been revenue, but due to the lack of specific and unified instructions on payment for technical services of diagnostic imaging based on the PACS system, the Company still does not have enough reliable basis to fully determine the economic benefits that will be obtained from this leasing and business cooperation. Currently, the Company is mainly collecting fees for providing maintenance services, maintenance of machinery and equipment as well as 24/24 technical support fees for the PACS system.

11. Construction in progress

	<u>Beginning Balance</u>	<u>Costs incurred during the year</u>	<u>Transfer to fixed assets</u>	<u>Year-end Balance</u>
Fixed asset purchases	26,588,372,787	13,554,551,470	(19,451,921,349)	20,691,002,908
Machine systems in hospitals	2,953,624,566	-	-	2,953,624,566
PACS System at Medical Centers	23,634,748,221	13,554,551,470	(19,451,921,349)	17,737,378,342
Total	<u>26,588,372,787</u>	<u>13,554,551,470</u>	<u>(19,451,921,349)</u>	<u>20,691,002,908</u>

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Financial Statements (Cont)**12. Long-term financial investment
a, Investment in Subsidiaries**

	Year-end Balance		Beginning Balance	
	Cost	Preventive	Cost	Preventive
<i>Investment in subsidiaries</i>	<i>1,284,140,000,000</i>	<i>(36,715,580,781)</i>	<i>1,289,040,000,000</i>	<i>(13,410,514,338)</i>
Viet My Hospital Investment Joint Stock Company (Ownership ratio 83.33%)	250,000,000,000	(18,079,224,693)	250,000,000,000	(8,429,639,324)
Ha Long Kyoto Technology Development Joint Stock Company (Ownership ratio 99%)	108,900,000,000	(8,732,280,347)	108,900,000,000	(58,454,016)
Kyoto Bai Chay Clinic Joint Stock Company (Ownership ratio 98%)	49,000,000,000	-	49,000,000,000	(1,019,226,739)
Song Hau New Technology Application Research Joint Stock Company (Ownership ratio 98%)	147,000,000,000	-	147,000,000,000	-
Vietnam National Software Production Joint Stock Company (Ownership ratio 98%)	29,400,000,000	-	29,400,000,000	-
Ha Dong Clinic Joint Stock Company (Ownership ratio 98%)	77,420,000,000	-	77,420,000,000	(981,100,857)
Hoa Binh Clinic Joint Stock Company (Ownership ratio 98%)	122,500,000,000	(9,904,075,741)	122,500,000,000	(1,037,005,209)
Viet Tri Clinic Joint Stock Company (Ownership ratio 98%)	106,820,000,000	-	106,820,000,000	(3,475,927)
Gia Lam High-Tech Clinic Joint Stock Company (Ownership ratio 98%)	77,420,000,000	-	77,420,000,000	(759,111,361)
Medicare Can Tho Clinic Joint Stock Company (Ownership ratio 98%)	77,420,000,000	-	77,420,000,000	(434,480,816)
Medicare Hau Giang Clinic Joint Stock Company (Ownership ratio 98%)	77,420,000,000	-	77,420,000,000	(164,978,524)
Medicare Soc Trang Clinic Joint Stock Company (Ownership ratio 98%)	77,420,000,000	-	77,420,000,000	(403,451,229)
Medicare Nga Bay Clinic Joint Stock Company (Ownership ratio 98%)	77,420,000,000	-	77,420,000,000	-
Leopard Solutions Joint Stock Company (Ownership ratio 75%)	6,000,000,000	-	6,000,000,000	-
Golab Vung Tau Laboratory Center Joint stock Company (Ownership ratio 49%)	-	-	4,900,000,000	(119,590,336)
Total	1,284,140,000,000	(36,715,580,781)	1,289,040,000,000	(13,410,514,338)

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Financial Statements (Cont)**b, Investment in joint ventures and associates**

These are investments in a chain of affiliated companies to establish clinics and testing centers across the country. The details of investments as at December 31, 2024 are presented below:

	Year-end Balance			Beginning Balance	
	Cost	Preventive	Actual capital contribution ratio	Cost	Preventive
<i>Investment in joint ventures and associates</i>	<i>153,300,000,000</i>	<i>(921,745,039)</i>		-	-
Golab Phap Van Laboratory Center Joint Stock Company	10,500,000,000	(31,339,259)	35%	-	-
Famicare Phap Van Joint Stock Company (*)	10,500,000,000	(12,655,367)	35%	-	-
Golab Go Vap Laboratory Center Joint Stock Company	10,500,000,000	(29,123,121)	35%	-	-
Nghe An Clinic Joint Stock Company	10,500,000,000	(35,878,195)	35%	-	-
Ba Dinh Clinic Joint Stock Company (*)	10,500,000,000	(459,037,548)	49%	-	-
Golab Bac Lieu Laboratory Center Joint Stock Company	10,500,000,000	(33,757,173)	35%	-	-
Golab Tien Giang Laboratory Center Joint Stock Company	10,500,000,000	(22,457,100)	35%	-	-
Golab Binh Duong Laboratory Center Joint Stock Company (*)	10,500,000,000	(12,406,284)	35%	-	-
Famicare Tuyen Quang Joint Stock Company	10,500,000,000	(15,183,088)	35%	-	-
Golab Ha Giang Laboratory Center Joint Stock Company (*)	14,700,000,000	(3,748,697)	49%	-	-
Huu Nghi Medicare Clinic Joint Stock Company	14,700,000,000	(116,686,997)	49%	-	-
Golab Ninh Binh Laboratory Center Joint Stock Company	14,700,000,000	(66,206,661)	49%	-	-
Golab Vung Tau Laboratory Center Joint Stock Company (*)	14,700,000,000	(83,265,549)	49%	-	-
Total	153,300,000,000	(921,745,039)		-	-

(*) These associate companies have been established but have not yet formed or hold insignificant assets for business operations.

13. Short-term trade payables

	Year-end Balance	Beginning Balance
TSG Trading and Service business Company limited	-	4,902,721,200
Phuong Dong Technology Engineering Joint Stock Company	-	232,965,920
Vietnam Medical Technology Company Limited	-	104,750,000
Branch of Duy Minh Equipment Company Limited	650,444,922	650,444,922
JWB CO.,LTD	298,643,120	-
Other suppliers	199,923,634	182,398,437
Total	1,149,011,676	6,073,280,479

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Financial Statements (Cont)**14. Taxes and amounts payable to the State**

	Beginning-of- year payable amount	Amount payable during the year	Amount actually paid during the year	End-of-year payable amount	End-of-year receivable amount
VAT on domestic sales	-	887,523,548	-	887,523,548	-
VAT on imported goods	-	14,932,156	(14,932,156)	-	-
Corporate income tax (CIT)	-	-	(200,000,000)	-	200,000,000
Personal income tax (PIT)	6,016,462	42,924,987	(37,745,824)	11,195,625	-
Other taxes	-	6,000,000	(6,000,000)	-	-
Total	6,016,462	951,380,691	(258,677,980)	898,719,173	200,000,000

The company's tax finalization will be subject to inspection by the tax authorities. Since the application of laws and regulations regarding taxes on various types of transactions can be interpreted in multiple ways, the tax amount presented in the financial statements may be subject to change based on the decision of the tax authorities.

Value-Added Tax

The company pays value-added tax (VAT) according to the credit-invoice method. The VAT rate is as follows:

- Revenue from the sale of medical supplies and equipment	5%
- Revenue from providing testing, imaging, and diagnostic services in collaboration with hospitals	Exempt from tax
- Other activities	8%, 10%

Corporate income tax

Corporate income tax is calculated based on taxable income for the year, with an applicable tax rate of 20%.

Other type of taxes

Other taxes, which the company declares and pays according to regulations.

15. Short-term payable expenses

	Year-end Balance	Beginning Balance
Interest expense payable	19,438,461,246	13,824,060,840
Other short-term payable expenses	322,000,000	150,000,000
Total	19,760,461,246	13,974,060,840

16. Other short-term payables

	Year-end Balance	Beginning Balance
Dividends payable (*)	75,924,090,000	75,924,090,000
Other short-term payables	7,180,000	7,180,000
Total	75,931,270,000	75,931,270,000

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Financial Statements (Cont)

(*) The 2019 dividend must be paid to shareholders according to the shareholder list as of January 12, 2021. Resolution No. 2502/NQ-HĐQT dated February 25, 2025 of the Board of Directors on changing the time for paying dividends in 2019, accordingly the time for paying dividends is as follows: Payment of the first installment on January 28, 2026; Payment of the second installment on July 28, 2026.

Reason for change: The company is expanding its production and business activities and investing in equipment and machinery for important projects. To ensure progress, the company uses available capital to order necessary equipment.

17. Short-term loans and finance leases

	Year-end Balance		Beginning Balance	
	Value	Number of debtors	Value	Number of debtors
Short term bank loans	24,625,095,827	24,625,095,827	31,778,533,650	31,778,533,650
<i>An Binh Commercial Joint</i>				
<i>Stock Bank - Hanoi Branch</i>	-	-	155,368,358	155,368,358
<i>BVBank (*)</i>	24,625,095,827	24,625,095,827	31,623,165,292	31,623,165,292
Total	24,625,095,827	24,625,095,827	31,778,533,650	31,778,533,650

(*) Loan under Credit Contract No. 0041900059900 dated November 28, 2019; Amendment and Supplement Agreement dated July 6, 2021 regarding adjustment of the principal repayment schedule. Loan amount: VND 40,000,000,000; Purpose of the loan: Purchase of medical machinery and equipment for production and business operations; Interest rate: 11.5% per annum; Loan term: 48 months. Collateral: medical machinery and equipment under Movable Asset Mortgage Contract No. 0041900060000 dated November 28, 2019.

As of the issuance date of this report, the above loan is overdue. The extension request period stated in Official Letter No. 05/2024/CV-AMV of the Company was October 2024, and it was approved by BVBank in Official Letter No. 212/2024/BVbank/CV-QL&THN dated April 9, 2024. However, as of now, the Company has not yet fully repaid the aforementioned principal amount and is continuing to work with the Bank to request an extension.

Details of short-term loans incurred during the period as follows:

	Beginning Balance	Amount of loan incurred during the year	Loan amount repaid during the year	Year-end Balance
<i>An Binh Commercial Joint</i>				
<i>Stock Bank - Hanoi Branch</i>	155,368,358	-	(155,368,358)	-
<i>BVBank</i>	31,623,165,292	-	(6,998,069,465)	24,625,095,827
Total	31,778,533,650	-	(7,153,437,823)	24,625,095,827

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Financial Statements (Cont)**18. Owner's Equity***a, Statement of Changes in Owners' Equity*

	<u>Owner's equity</u>	<u>Capital surplus</u>	<u>Profit after tax not distributed</u>	<u>Total</u>
Last year's opening number	1,311,056,500,000	(395,300,000)	214,270,463,911	1,524,931,663,911
Profit in the previous year	-	-	32,624,773,976	32,624,773,976
Last year ending balance	1,311,056,500,000	(395,300,000)	246,895,237,887	1,557,556,437,887
Beginning balance of this year	1,311,056,500,000	(395,300,000)	246,895,237,887	1,557,556,437,887
Profit in the current year	-	-	(12,651,723,096)	(12,651,723,096)
Ending balance of this year	1,311,056,500,000	(395,300,000)	234,243,514,791	1,544,904,714,791

b, Breakdown of capital contributions by owners:

	<u>Year-end Balance</u>		<u>Beginning Balance</u>	
	<u>Value</u>	<u>Ownership ratio</u>	<u>Value</u>	<u>Ownership ratio</u>
Other shareholders	1,311,056,500,000	100,00%	1,311,056,500,000	100,00%
Total	1,311,056,500,000	100,00%	1,311,056,500,000	100,00%

c, Stocks

	<u>Year-end Balance</u>	<u>Beginning Balance</u>
Number of shares registered for issuance	131,105,650	131,105,650
Number of shares issued/sold to the public	131,105,650	131,105,650
- Common shares	131,105,650	131,105,650
- Preferred shares	-	-
Number of outstanding shares	131,105,650	131,105,650
- Common shares	131,105,650	131,105,650
- Preferred shares	-	-

Outstanding shares face value: 10,000 VND.

VI. ADDITIONAL INFORMATION ON ITEMS PRESENTED IN THE INCOME STATEMENT**1. Revenue from sales and service provision**

	<u>This year</u>	<u>Last year</u>
Revenue from sales of goods and provision of services	169,364,910,851	53,332,389,363
Revenue deductions		
Returned goods	-	(3,028,000)
Net revenue from sales and services	169,364,910,851	53,329,361,363

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Financial Statements (Cont)*Including revenue from sales of goods and provision of services to related parties:*

	This year	Last year
Famicare Kien Giang Joint Stock Company	4,504,895,000	-
Famicare Quang Binh Joint Stock Company	4,504,895,000	-
Famicare Vinh Long Joint Stock Company	7,305,177,000	-
Huu Nghi Medicare Clinic Joint Stock Company	222,000,000	-
Golab Ninh Binh Laboratory Center Joint Stock Company	39,000,000	-
Golab An Giang Laboratory Center Joint Stock Company	2,804,882,000	-
Golab Bac Ninh Laboratory Center Joint Stock Company	7,344,177,000	-
Golab Bien Hoa Laboratory Center Joint Stock Company	3,850,000,000	-
Golab Dong Thap Laboratory Center Joint Stock Company	2,843,882,000	-
Golab Gia Lai Laboratory Center Joint Stock Company	2,829,882,000	-
Golab Ha Tinh Laboratory Center Joint Stock Company	4,568,895,000	-
Golab Hai Duong Laboratory Center Joint Stock Company	7,463,177,000	-
Golab Hai Phong Laboratory Center Joint Stock Company	3,001,882,000	-
Golab Hung Yen Laboratory Center Joint Stock Company	7,330,177,000	-
Golab Kien Giang Laboratory Center Joint Stock Company	6,654,882,000	-
Golab Phap Van Laboratory Center Joint Stock Company	220,000,000	-
Golab Quang Binh Laboratory Center Joint Stock Company	3,039,282,000	-
Golab Tan An Laboratory Center Joint Stock Company	2,820,382,000	-
Golab Vinh Long Laboratory Center Joint Stock Company	2,843,882,000	-
Golab Vinh Phuc Laboratory Center Joint Stock Company	7,349,895,000	-
2. Cost of goods sold		
	This year	Last year
Cost of goods sold, services provided	160,394,730,660	46,892,026,814
Total	160,394,730,660	46,892,026,814
3. Financial income		
	This year	Last year
Deposit interest, loan interest	513,202	122,029,931
Dividends, profits shared	10,000,000,000	42,896,801,893
Exchange rate difference profit	-	71,561,644
Total	10,000,513,202	43,090,393,468
4. Financial expenses		
	This year	Last year
Interest expense	5,638,032,048	7,679,639,455
Exchange rate difference loss incurred	-	210,788,247
Provision/(Reversal) of investment loss provision	24,226,811,482	3,060,619,275
Total	29,864,843,530	10,951,046,977

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Financial Statements (Cont)**5. Cost of sales**

	This year	Last year
Employee expenses	295,095,140	223,433,328
Material and packaging costs	-	76,249,796
Outsourced service costs	25,977,202	126,377,828
Other expenses	-	1,177,400,000
Total	321,072,342	1,603,460,952

6. Business management costs

	This year	Last year
Employee expenses	3,142,836,806	2,411,040,790
Office supplies expenses	29,931,820	11,249,998
Depreciation of fixed assets	5,992,428	2,480,736
Taxes, duties and fees	6,000,000	6,000,000
Provision/(Reversal) for doubtful debts	183,949,843	(41,450,116)
Outsourced service costs	1,808,758,235	1,475,793,683
Other expenses	148,396,815	26,350,964
Total	5,325,865,947	3,891,466,055

7. Other income

	This year	Last year
Gain on disposal of fixed assets	3,903,888,904	-
Other income	20,416,672	6,390
Total	3,924,305,576	6,390

8. Other costs

	This year	Last year
Loss on disposal of fixed assets	-	113,847,881
Depreciation of fixed assets not used in production and business	-	341,543,628
Penalties for late payment of taxes and insurance	34,940,246	1,594,938
Total	34,940,246	456,986,447

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Financial Statements (Cont)**9. Current corporate income tax expense**

Corporate income tax payable during the period is estimated as follows:

	<u>This year</u>	<u>Last year</u>
Total accounting profit before tax	(12,651,723,096)	32,624,773,976
Adjustments to increase or decrease accounting profit to determine profit subject to corporate income tax:	(6,073,398,625)	(42,667,521,525)
- Increase adjustments	3,926,601,375	229,280,368
<i>Depreciation of fixed assets not serving production and business</i>	3,891,661,129	4,821,345,036
<i>Penalty for late payment of tax and insurance</i>	34,940,246	1,594,938
- Adjustments for reduction	(10,000,000,000)	(42,896,801,893)
<i>Dividends, profits shared</i>	(10,000,000,000)	(42,896,801,893)
Taxable income	(18,725,121,721)	(10,042,747,549)
Taxable income	(18,725,121,721)	(10,042,747,549)
Corporate income tax rate	20%	20%
Total Corporate Income Tax payable	-	-

10. Basic earnings per share

The Company does not present this indicator in the financial statements because, in accordance with Accounting Standard No. 30 – “Earnings per Share”, where an enterprise is required to prepare both separate financial statements and consolidated financial statements, it is only required to disclose earnings per share in the consolidated financial statements as prescribed by this standard.

11. Expenses by category

	<u>This year</u>	<u>Last year</u>
Cost of raw materials	29,931,820	87,499,794
Labor costs	3,437,931,946	2,634,474,118
Fixed asset depreciation costs	9,667,514,548	11,086,254,165
Taxes, fees and charges	6,000,000	6,000,000
Provision/(Reversal) of provision for doubtful debts	183,949,843	(41,450,116)
Outsourcing service costs	1,835,935,437	1,602,171,511
Other costs	148,396,815	1,203,750,964
Total	15,309,660,409	16,578,700,436

VII. OTHER INFORMATION**1. Information about related parties**

Stakeholders of the Enterprise include: key management members, individuals related to key management members and other stakeholders.

A, Transactions and balances with key management members and individuals related to key management members

Key management members include: members of the Board of Directors and members of the Executive Board (Board of Directors, Chief Accountant). Individuals related to key management members are close family members of key management members.

Key Management Members' Compensation:

	<u>This year</u>	<u>Last year</u>
Mrs. Dang Nhi Nuong	261,500,000	241,500,000

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Financial Statements (Cont)

During the period, the unit did not have any transactions with related parties.

B, Transactions with other related parties

Other related parties to the Enterprise include: subsidiaries, affiliated companies, individuals with direct or indirect voting rights in the Enterprise and close members of their families, enterprises managed by key management personnel and individuals with direct or indirect voting rights of the Enterprise and close members of their families

Related parties include:	Relationship
Viet My Hospital Investment Joint Stock Company	Subsidiary
Ha Long Kyoto Technology Development Joint Stock Company	Subsidiary
Bai Chay Kyoto Clinic Joint Stock Company	Subsidiary
Song Hau New Technology Application Research Joint Stock Company	Subsidiary
Vietnam National Software Production Joint Stock Company	Subsidiary
Ha Dong Clinic Joint Stock Company	Subsidiary
Hoa Binh Clinic Joint Stock Company	Subsidiary
Viet Tri Clinic Joint Stock Company	Subsidiary
Gia Lam High-Tech Clinic Joint Stock Company	Subsidiary
Can Tho Medicare Clinic Joint Stock Company	Subsidiary
Hau Giang Medicare Clinic Joint Stock Company	Subsidiary
Soc Trang Medicare Clinic Joint Stock Company	Subsidiary
Nga Bay Medicare Clinic Joint Stock Company	Subsidiary
Leopard Solutions Joint Stock Company	Associate company
Golab Phap Van Laboratory Center Joint Stock Company	Associate company
Famicare Phap Van Joint Stock Company	Associate company
Golab Go Vap Laboratory Center Joint Stock Company	Associate company
Nghe An Clinic Joint Stock Company	Associate company
Ba Dinh Clinic Joint Stock Company	Associate company
Golab Bac Lieu Laboratory Center Joint Stock Company	Associate company
Golab Tien Giang Laboratory Center Joint Stock Company	Associate company
Golab Binh Duong Laboratory Center Joint Stock Company	Associate company
Famicare Tuyen Quang Joint Stock Company	Associate company
Golab Ha Giang Laboratory Center Joint Stock Company	Associate company
Huu Nghi Medicare Clinic Joint Stock Company	Associate company
Golab Ninh Binh Laboratory Center Joint Stock Company	Associate company
Golab Vung Tau Laboratory Center Joint Stock Company	Associate company

Transactions with other related parties

The main transactions during the period between the Company and other related parties are as follows:

	This year	Last year
Viet Tri Clinic Joint Stock Company		
Receivables from advances for goods purchase	-	46,000,000,000
Collection of advances received	46,000,000,000	-
Vietnam National Software Production Joint Stock Company		
Dividends and distributed profits receivable	5,000,000,000	-

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Financial Statements (Cont)

	<u>This year</u>	<u>Last year</u>
Viet My Hospital Investment Joint Stock Company		
Payables for goods purchased	-	7,000,000,000
Payment for goods purchased	-	43,962,841,000
Offsetting of receivables and payables	-	7,350,000,000
Song Hau New Technology Application Research Joint Stock Company		
Dividend receivable	-	18,686,817,489
Vietnam National Software Production Joint Stock Company		
Dividend receivable	10,000,000,000	12,000,000,000
Receive dividends and profits	5,000,000,000	12,000,000,000
Pay for goods	-	440,000,000
Bai Chay Kyoto Clinic Joint Stock Company		
Receivables from advances for goods purchase	-	4,100,000,000
Golab Phap Van Laboratory Center Joint Stock Company		
Receivables from capital support	2,500,000,000	-
Collection of capital support	2,500,000,000	-
Famicare Phap Van Joint Stock Company		
Receivables from capital support	2,500,000,000	-
Collection of capital support	2,500,000,000	-
Golab Tien Giang Laboratory Center Joint Stock Company		
Receivables from capital support	1,030,000,000	-
Collection of capital support	1,030,000,000	-
Golab Binh Duong Laboratory Center Joint Stock Company		
Receivables from capital support	4,000,000,000	-
Collection of capital support	3,500,000,000	-
The Company made capital contributions to subsidiaries and associates during the year as follows:		
Golab Phap Van Laboratory Center Joint Stock Company	10,500,000,000	-
Famicare Phap Van Joint Stock Company	10,500,000,000	-
Golab Go Vap Laboratory Center Joint Stock Company	10,500,000,000	-
Nghe An Clinic Joint Stock Company	10,500,000,000	-
Ba Dinh Clinic Joint Stock Company	10,500,000,000	-
Golab Bac Lieu Laboratory Center Joint Stock Company	10,500,000,000	-
Golab Tien Giang Laboratory Center Joint Stock Company	10,500,000,000	-
Golab Binh Duong Laboratory Center Joint Stock Company	10,500,000,000	-
Famicare Tuyen Quang Joint Stock Company	10,500,000,000	-
Golab Ha Giang Laboratory Center Joint Stock Company	14,700,000,000	-

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Financial Statements (Cont)

	This year	Last year
Huu Nghi Medicare Clinic Joint Stock Company	14,700,000,000	-
Golab Ninh Binh Laboratory Center Joint Stock Company	14,700,000,000	-
Golab Vung Tau Laboratory Center Joint Stock Company	9,800,000,000	-

The Company had sales and service transactions with related parties during the year as follows:	Receivables from sales of goods and services	Collect sales
Huu Nghi Medicare Clinic Joint Stock Company	244,200,000	-
Golab Phap Van Laboratory Center Joint Stock Company	242,000,000	-
Golab Hai Phong Laboratory Center Joint Stock Company	3,022,070,200	90,000,000
Golab Hai Duong Laboratory Center Joint Stock Company	7,479,494,700	320,000,000
Golab Hung Yen Laboratory Center Joint Stock Company	7,333,194,700	320,000,000
Golab Quang Binh Laboratory Center Joint Stock Company	3,043,210,200	130,000,000
Golab Dong Thap Laboratory Center Joint Stock Company	2,848,270,200	80,000,000
Golab Vinh Long Laboratory Center Joint Stock Company	2,848,270,200	80,000,000
Golab An Giang Laboratory Center Joint Stock Company	2,805,370,200	80,000,000
Famicare Kien Giang Joint Stock Company	4,505,384,500	170,000,000
Golab Kien Giang Laboratory Center Joint Stock Company	6,847,870,200	80,000,000
Golab Bac Ninh Laboratory Center Joint Stock Company	7,348,594,700	220,000,000
Golab Vinh Phuc Laboratory Center Joint Stock Company	7,494,884,500	130,000,000
Golab Ninh Binh Laboratory Center Joint Stock Company	42,900,000	-
Golab Ha Tinh Laboratory Center Joint Stock Company	4,575,784,500	190,000,000
Famicare Quang Binh Joint Stock Company	4,505,384,500	190,000,000
Golab Bien Hoa Laboratory Center Joint Stock Company	4,042,500,000	-
Golab Gia Lai Laboratory Center Joint Stock Company	2,832,870,200	-
Famicare Vinh Long Joint Stock Company	7,305,694,700	230,000,000
Golab Tan An Laboratory Center Joint Stock Company	2,822,420,200	-
Viet My Hospital Investment Joint Stock Company	2,835,000,000	-

At the end of the accounting period, debts with related parties are presented in detail in notes V.3; V.4; V.5 and V.11./.

2. Fair value of financial assets and liabilities

	Book value		Fair value	
	Year-end Balance	Beginning Balance	Year-end Balance	Beginning Balance
Financial assets				
Cash and cash equivalents	2,123,348,100	6,404,911,296	2,123,348,100	6,404,911,296
Accounts receivable	153,111,019,347	39,455,959,291	153,111,019,347	39,455,959,291
Other receivables	6,107,640,662	514,885,909	6,107,640,662	514,885,909
Total	161,342,008,109	46,375,756,496	161,342,008,109	46,375,756,496
Financial liabilities				
Loans and Debts	24,625,095,827	31,778,533,650	24,625,095,827	31,778,533,650
Payable to seller	1,149,011,676	6,073,280,479	1,149,011,676	6,073,280,479
Other payables	95,691,731,246	89,905,330,840	95,691,731,246	89,905,330,840
Total	121,465,838,749	127,757,144,969	121,465,838,749	127,757,144,969

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Financial Statements (Cont)

The fair value of financial assets and financial liabilities is reflected at the amount at which the financial instruments could be exchanged in a current transaction between knowledgeable and willing parties.

The Company uses the following methods and assumptions to estimate fair value:

- The fair value of cash and cash equivalents, trade receivables, loans, other receivables, borrowings, trade payables and other short-term payables is equivalent to the book value (net of provisions for estimated uncollectibility) of these items due to their short maturity.
- The fair value of loans, trade receivables, other receivables, borrowings, trade payables and other long-term payables, held-to-maturity investments that are not listed on the stock market and do not have a trading price announced by 3 securities companies is estimated by discounting cash flows at the interest rate applicable to debts with similar characteristics and remaining maturity.

3. Credit risk

Credit risk is the risk that a party to a contract will not be able to perform its obligations resulting in financial loss to the Company.

The Company is exposed to credit risk from its operating activities (primarily trade receivables) and financing activities (bank deposits, loans and other financial instruments).

Accounts receivable

The Company minimizes credit risk by only dealing with financially sound entities, requiring letters of credit to be opened for entities that are trading for the first time or have no information on their financial capabilities, and having accounts receivable staff regularly monitor receivables to urge collection. On this basis, and the Company's receivables are related to many different customers, credit risk is not concentrated on a particular customer.

Deposits

Most of the bank deposits of the company is deposited in large, reputable banks in Vietnam. The company finds that the level of concentration of credit risk for bank deposits is low.

4. Risk/liquidity risk

Liquidity risk is the risk the company had difficulty meeting its financial obligations due to lack of funds.

The Board of Directors has ultimate responsibility for liquidity risk management. The Company's liquidity risk arises primarily from the mismatch of maturities between its financial assets and financial liabilities.

The Company manages liquidity risk by maintaining an appropriate level of cash and cash equivalents and borrowings at levels deemed necessary by the Board. The leadership considers it sufficient to meet the operational needs of the company aims to minimize the impact of cash flow fluctuations.

The maturity of financial liabilities based on undiscounted contractual payments is as follows:

	1 year or less	Over 1 year to 5 years	Over 5 years	Total
Year-end Balance				
Loans and Debts	24,625,095,827	-	-	24,625,095,827
Payable to seller	1,149,011,676	-	-	1,149,011,676
Other payables	95,691,731,246	-	-	95,691,731,246
Total	121,465,838,749	-	-	121,465,838,749
Beginning Balance				
Loans and Debts	31,778,533,650	-	-	31,778,533,650
Payable to seller	6,073,280,479	-	-	6,073,280,479
Other payables	89,905,330,840	-	-	89,905,330,840
Total	127,757,144,969	-	-	127,757,144,969

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City
FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Financial Statements (Cont)

The Company believes that the concentration of risk with respect to debt repayment is low. The Company is able to repay its debts when they fall due from cash flows from operations and proceeds from maturing financial assets.

5. Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk includes three types: currency risk, interest rate risk and other price risk.

The sensitivity analyses presented below are based on a constant value of net debt, with the ratio of fixed-rate debt to floating-rate debt remaining constant.

Foreign exchange risk

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.

Interest rate risk of Company mainly related to money and loans.

The Company manages interest rate risk by analyzing market conditions to obtain the most favorable interest rates while remaining within its risk management limits.

Other price risks

Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices other than changes in interest rates and foreign exchange rates.

6. Events occurring after the reporting date

- American VietNameese Biotech INC ("AMV") with many years of experience in the medical field: providing machinery and equipment systems, supplying consumables,... Facing the increasing demand for health care services, cancer screening and home health care, learning from the infusion center model - built and operated according to Japan's international safety standards - specializing in providing drug, vitamin, protein, therapy and water infusion services to improve patient health, is gradually becoming a popular trend in many countries such as Japan, the US, Thailand. However, in Vietnam, this model is still quite new and has not been widely deployed. At the same time, after reviewing and evaluating the overall mobile examination vehicle project, investment project, joint venture linking medical image archiving and transmission systems (PACS system) with hospitals that the company previously pursued, it did not meet expectations as expected. Therefore, the company boldly divested all or part of those projects, the Company has determined a strategy to strongly develop the clinic and infusion center model in the coming time. Currently, the Company is carrying out the necessary procedures to put the chain of clinic companies in all 63 provinces and cities across the country into operation, with the expectation of providing early, reliable diagnostic tests at the most cost-effective cost at the chain of testing centers. This issue was also approved at the 2024 Annual General Meeting of Shareholders.

- Resolution of the Board of Directors No. 0601/2025/NQ-HĐQT dated January 6, 2025 and Resolution of the Board of Directors No. 1701/2025/NQ-HĐQT dated January 17, 2025 on receiving the transfer of VND 204,227,000,000 of contributed capital at Phu Tho Provincial Obstetrics and Pediatrics Hospital from Sara Vietnam Joint Stock Company. The transfer value from Sara Vietnam Joint Stock Company under contract No. 01/2025/HĐCN/SARA-VIETMY dated February 15, 2025 is VND 204,227,000,000. Up to now, the Company has paid the entire amount of VND 204,227,000,000. However, according to Resolution of the Board of Directors No. 1604/2025/NQ-HĐQT dated April 16, 2025, the Company decided to withdraw capital early from Phu Tho Maternity and Pediatrics Hospital, the capital withdrawal plan is from 2025 to 2028. Up to now, the Hospital has transferred 9,5 billion to the company.

AMERICAN VIETNAMESE BIOTECH INC

Address: 4th Floor, Phu Ma Duong Building, 85 Hoang Van Thai, Tan Phu Ward, District 7, Ho Chi Minh City

FINANCIAL STATEMENTS

For the fiscal year ending December 31, 2024

Notes to the Financial Statements (Cont)

- Resolution of the Board of Directors No. 2502.01/2025/NQ-HDQT dated February 25, 2025 on divestment of investment capital at Vietnam National Software Production Joint Stock Company.

7. Comparison information

The comparative figures presented in these consolidated financial statements are derived from the audited financial statements for the fiscal year ended December 31, 2023, which were audited by TTP Auditing Co., Ltd.

Certain line items in the Consolidated Balance Sheet, the Consolidated Income Statement, and the Consolidated Cash Flow Statement for the year 2023 have been retrospectively adjusted due to changes in the recognition of overdue interest expenses related to the loan from Viet Capital Commercial Joint Stock Bank (Viet Capital Bank). The details of these adjustments are as follows:

		Figures based on the audited financial statements of the previous year			
	Code		Restated figures	Adjusted figures	
Balance sheet					
Short-term payable expenses	315	9,620,385,088	4,353,675,752	13,974,060,840	
Undistributed profit after tax	421	251,248,913,639	(4,353,675,752)	246,895,237,887	
Undistributed profit after tax accumulated to the end of previous period	421a	215,505,662,285	(1,235,198,374)	214,270,463,911	
Undistributed profit this period	421b	35,743,251,354	(3,118,477,378)	32,624,773,976	
Business performance report					
Financial costs	22	7,832,569,599	3,118,477,378	10,951,046,977	
Including: interest expense	23	4,561,162,077	3,118,477,378	7,679,639,455	
Total accounting profit before tax	50	35,743,251,354	(3,118,477,378)	32,624,773,976	
Profit after corporate income tax	60	35,743,251,354	(3,118,477,378)	32,624,773,976	
Cash flow statement					
Profit before tax	03	35,743,251,354	(3,118,477,378)	32,624,773,976	
Interest expense	06	4,561,162,077	3,118,477,378	7,679,639,455	

Prepared on 28 May, 2025

Prepared by



Nguyen Minh Hoa

Chief Accountant



Le Thi Viet Ha

Director



Dang Nhi Nuong